Abstract
Introduction
The development of imatinib as a therapeutic agent targeting BCR-ABL has increased the treatment options for chronic myeloid leukemia (CML) by significantly impacting outcomes, and imatinib is recommended by treatment guidelines as the first-line therapy. However, treatment of maternal CML with imatinib during gestation is not recommended because of the potential risk to the fetus.
Materials and methods
We describe the clinical presentation, course and outcome of one pregnant patient with CML who was treated with imatinib. We review all pregnancies associated with imatinib documented in the literature.
Case presentation
A 27-year-old pregnant patient was diagnosed to have Philadelphia chromosome positive chronic phase CML in August 2007. Imatinib was administered (400 mg/day) between the 21st and 39th weeks of gestation. The patient tolerated the drug well and achieved complete hematological and cytogenetic remission. There were no imatinib-related maternal complications during the pregnancy. Fetal growth remained normal as well as amniotic fluid volume estimation. Labor was induced at the 39th gestational week, resulting in the uneventful vaginal delivery of a healthy male infant without any congenital anomaly. Umbilical cord blood and infant peripheral blood were collected at delivery. No postnatal complications occurred; however, imatinib was present in the umbilical cord blood (338 ng/mL) and in the infant’s peripheral blood (478 ng/mL). Breast milk was collected on different postpartum days, and concentrations of imatinib were detected. At 10 months of age, the baby had normal growth and development.
Conclusions
In light of reported cases and our experience, treatment of CML during the second and third trimesters of gestation and breast feeding seems to be safe, but the data are still limited and the effects of chronic exposure of infants to imatinib are not known. We think that each case should be examined and considered independently, and decisions should be individualized.
Similar content being viewed by others
References
Kyriakides S (2008) Psychosocial issues in young women facing cancer and pregnancy: the role of patient advocacy. Recent Results Cancer Res 178:247–252. doi:10.1007/978-3-540-71274-9_21
Ali R, Ozkalemkas F, Ozcelik T, Ozkocaman V, Ozan U, Kimya Y, Koksal N, Gulten T, Yakut T, Tunali A (2005) Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 29:971–973. doi:10.1016/j.leukres.2005.01.009
Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Ozan U, Kimya Y, Tunali A (2004) Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol 34:215–217. doi:10.1093/jjco/hyh038
Hensley ML, Ford JM (2003) Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 40(2(Suppl 2)):21–25. doi:10.1016/S0037-1963(03)70016-X
Goldman JM (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110:2828–2837. doi:10.1182/blood-2007-04-038943
Henkes M, van der Kuip H, Aulitzky WE (2008) Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manage 4:163–187
Ault P, Kantarjian H, O’Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J (2006) Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 24:1204–1208. doi:10.1200/JCO.2005.04.6557
Ali R, Ozkalemkas F, Ozcelik T, Ozkocaman V, Ozkan A (2006) Imatinib and pregnancy. J Clin Oncol 24:3812–3813. doi:10.1200/JCO.2006.06.9310
Klaasen R, de Jong P, Wijermans PW (2007) Successful management of chronic myeloid leukaemia with leucapheresis during a twin pregnancy. Neth J Med 65:147–149
Atallah E, Kantarjian H, Cortes J (2007) Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma 7(Suppl 3):S105–S112. doi:10.3816/CLM.2007.s.010
Heartin E, Walkinshaw S, Clark RE (2004) Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 45:1307–1308. doi:10.1080/10428190310001645195
Sotiropoulos D, Adamidou D, Athanasiadou A, Goulis DG, Fassas A, Anagnostopoulos A (2004) Two pregnancies resulting in a healthy newborn in a CML patient treated with imatinib. Blood 104 (Abstract 4694)
Fogliatto L, Brum C, Zago A, Faltoe T, Rodrigues F, Falhauber G, Leugeur D, Silla L (2005) Pregnancy during treatment with imatinib: a case report. Blood 106 (Abstract 4851)
AlKindi S, Dennison D, Pathare A (2005) Imatinib in pregnancy. Eur J Haematol 74:535–537. doi:10.1111/j.1600-0609.2005.00420.x
Prabhash K, Sastry PS, Biswas G, Bakshi A, Prasad N, Menon H, Parikh PM (2005) Pregnancy outcome of two patients treated with imatinib. Ann Oncol 16:1983–1984. doi:10.1093/annonc/mdi398
Choudhary DR, Mishra P, Kumar R, Mahapatra M, Choudhry VP (2006) Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 17:178–179. doi:10.1093/annonc/mdj065
Suppiah R, Kalaycio M (2006) Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester. Leuk Lymphoma 47:1149–1150. doi:10.1080/10428190500399029
Koh LP, Kanagalingam D (2006) Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. Int J Hematol 84:459–462. doi:10.1532/IJH97.A20610
Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ (2007) Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 27:241–243. doi:10.1038/sj.jp.7211665
Garderet L, Santacruz R, Barbu V, van den Akker J, Carbonne B, Gorin NC (2007) Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica 92:e9–e10. doi:10.3324/haematol.10935
Yilmaz M, Demirhan O, Kuçukosmanoglu E, Pehlivan M, Okan V, Balat O, Pehlivan S (2007) Pregnancy in patients with chronic myeloid leukemia treated with imatinib. Leuk Lymphoma 48:2454–2456. doi:10.1080/10428190701658751
Buyukbayrak EE, Ergen B, Karsidag YK, Kars B, Turan C, Argon D (2008) Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report. Arch Gynecol Obstet 278:161–163. doi:10.1007/s00404-007-0547-6
Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, Apperley JF (2008) The effects of imatinib on pregnancy outcome. Blood 111:5505–5508. doi:10.1182/blood-2007-10-114900
Meera V, Jijina F, Shrikande M, Madkaikar M, Ghosh K (2008) Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy. Leuk Res 32:1620–1622. doi:10.1016/j.leukres.2008.03.007
Dolai TK, Bhargava R, Mahapatra M, Mishra P, Seth T, Pati HP, Saxena R (2008) Is imatinib safe during pregnancy? Leuk Res (Epub ahead of print). doi:10.1016/j.leukres.2008.08.002
Skoumalova I, Vondrakova J, Rohon P, Rozmanova S, Jarosova M, Indrak K, Prochazka M, Santava A, Faber E (2008) Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152:121–123
Sorà F, De Matteis S, Bajer J, D’alò F, Leone G, Sica S (2008) Persistence of molecular remission throughout pregnancy in CML after imatinib. Leuk Res (Epub ahead of print). doi:10.1016/j.leukres.2008.09.12
Gambacorti-Passerini CB, Tornaghi L, Marangon E, Franceschino A, Pogliani EM, D’Incalci M, Zucchetti M (2007) Imatinib concentrations in human milk. Blood 109:1790
Shehata HA, Nelson-Piercy C (2000) Drugs to avoid in pregnancy. Curr Obstet Gynaecol 10:44–52. doi:10.1054/cuog.2000.0104
Pentheroudakis G, Pavlidis N (2006) Cancer and pregnancy: poena magna, not anymore. Eur J Cancer 42:126–140. doi:10.1016/j.ejca.2005.10.014
Cardonick E, Iacobucci A (2004) Use of chemotherapy during human pregnancy. Lancet Oncol 5:283–291. doi:10.1016/S1470-2045(04)01466-4
Fey MF, Surbek D (2008) Leukaemia and pregnancy. Recent Results Cancer Res 178:97–110. doi:10.1007/978-3-540-71274-9_10
Acknowledgments
We thank Dr. Murat Oktem (Duzen Research Laboratory, Ankara, Turkey) for the analyses of samples used in this study and Dr. Kemal Erguder (Novartis Pharmaceuticals, Izmir, Turkey) for collaboration. Duzen Research Laboratory is supported by a grant from Novartis Pharmaceutical Corporation.
Conflict of interest statement
Authors declare no potential financial disclosure or conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ali, R., Ozkalemkas, F., Kimya, Y. et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 280, 169–175 (2009). https://doi.org/10.1007/s00404-008-0861-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-008-0861-7